Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Int Pharmacopsychiatry. 1980;15(2):105-10.

    Alcohol withdrawal syndrome: treatment with trazodone.

    Abstract

    Central monoaminergic pathways dysfunction has been shown in the alcohol withdrawal syndrome of experimental animals: noradrenergic hyperfunction and serotonin transmission impairment is suggested by many studies. Trazodone is a new psychotropic drug which has a marked norepinephrine receptor blocking power; moreover, it inhibits serotonin reuptake and was fully effective in the treatment of man's withdrawal syndrome (17 alcoholic inpatients). The good therapeutical results make it conceivable that monoaminergic pathways dysfunction has an important pathophysiological role in the alcohol withdrawal syndrome of man also.

    PMID:
    6108298
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk